TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28991370

Group type: EXPERIMENTAL
Intervention: Ixekizumab 80 mg every 2 weeks (IXE Q2W)
Number of subjects: 3966

Group type: EXPERIMENTAL
Intervention: Ixekizumab 80 mg every 4 weeks (IXE Q4W)
Number of subjects: 3966

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3966

Group type: COMPARATOR
Intervention: Etanercept 50 mg biweekly
Number of subjects: 3966
Study: 27471808

Group type: EXPERIMENTAL
Intervention: Buccal infiltration with articaine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Inferior alveolar nerve block with lignocaine
Number of subjects: 30
Study: 24378475

Group type: EXPERIMENTAL
Intervention: Clinical hypothyroidism
Number of subjects: 1904

Group type: EXPERIMENTAL
Intervention: Subclinical hypothyroidism
Number of subjects: 1904

Group type: COMPARATOR
Intervention: Normal thyroid function
Number of subjects: 1904
Study: 22765978

Group type: EXPERIMENTAL
Intervention: CPOX4 variant boys
Number of subjects: 507

Group type: COMPARATOR
Intervention: CPOX4 non-variant boys
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: CPOX4 variant girls
Number of subjects: 507

Group type: COMPARATOR
Intervention: CPOX4 non-variant girls
Number of subjects: 507
Study: 20178033

Group type: EXPERIMENTAL
Intervention: Citalopram (selective serotonin reuptake inhibitor), duration: 12 weeks
Number of subjects: 2
Study: 18066957

Group type: EXPERIMENTAL
Intervention: Less tight control
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Tight control
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control group (less tight)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control group (tight)
Number of subjects: 132
Study: 15891594

Group type: EXPERIMENTAL
Intervention: Adenosine infusion with 99mTc‐tetrofosmin
Number of subjects: 51

Group type: COMPARATOR
Intervention: Resting state with 99mTc‐tetrofosmin
Number of subjects: 51
Study: 11907350

Group type: EXPERIMENTAL
Intervention: Currently available IBD therapies and those used in clinical trials for ulcerative colitis.
Number of subjects: 0
Study: 9830250

Group type: EXPERIMENTAL
Intervention: Low executive cognitive functioning (ECF)
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Difficult temperament
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Combined influence of low ECF and difficult temperament
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Low ECF
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: ECF
Number of subjects: 249
Study: 8006126

Group type: EXPERIMENTAL
Intervention: Artificial cycle (Goserelin 3.6 mg s.c. followed by hormone replacement therapy)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Progesterone supplementation (i.m. progesterone at a daily dose of 25‐50 mg for 14 days)
Number of subjects: 14
Study: 2722977

Group type: EXPERIMENTAL
Intervention: Theolong granules with a fat-rich breakfast
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Theodur-G granules with a fat-rich breakfast
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Theolong granules with a standard breakfast
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Theodur-G granules with a standard breakfast
Number of subjects: 5
Study: 786908

Group type: EXPERIMENTAL
Intervention: Diclophenac sodium (Voltaren)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 182

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study: 31198216

Group type: EXPERIMENTAL
Intervention: Polydexa with phenylephrine (experimental group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Topical decongestants (control group)
Number of subjects: 30
Study: 28844508

Group type: EXPERIMENTAL
Intervention: Evolocumab plus SOC
Number of subjects: 4802

Group type: COMPARATOR
Intervention: SOC
Number of subjects: 4802
Study: 26063066

Group type: EXPERIMENTAL
Intervention: 10-40 g LNSs/d containing milk powder
Number of subjects: 1932

Group type: EXPERIMENTAL
Intervention: 20 or 40 g milk-free LNSs/d
Number of subjects: 1932

Group type: COMPARATOR
Intervention: No supplement
Number of subjects: 1932

Group type: EXPERIMENTAL
Intervention: No milk LNS group
Number of subjects: 1932

Group type: EXPERIMENTAL
Intervention: Milk LNS group
Number of subjects: 1932
Study: 22647413

Group type: EXPERIMENTAL
Intervention: Amlodipine/valsartan 5/160 mg SPC
Number of subjects: 0

Group type: COMPARATOR
Intervention: Valsartan 160 mg
Number of subjects: 0
Study: 21943257

Group type: EXPERIMENTAL
Intervention: Olanzapine long-acting injection (LAI)
Number of subjects: 233

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 233
Study: 18572868

Group type: EXPERIMENTAL
Intervention: Combined therapy of medication with local hyperthermia (CRS-2280E system, anal administration of 1 Qianliean suppository, oral doxazosin 4 mg before bedtime for 2 weeks)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Simple local hyperthermia
Number of subjects: 76
Study: 16624082

Group type: EXPERIMENTAL
Intervention: Xuezhikang capsule
Number of subjects: 4860

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4860
Study: 12749484

Group type: EXPERIMENTAL
Intervention: Permethrin-treated bed nets (ITNs)
Number of subjects: 20915

Group type: COMPARATOR
Intervention: Control villages
Number of subjects: 20915
Study: 10919423

Group type: EXPERIMENTAL
Intervention: Oesophageal-tracheal Combitube 37 Fr SA
Number of subjects: 100

Group type: COMPARATOR
Intervention: Tracheal intubation
Number of subjects: 100
Study: 8828954

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin therapy (IVIG) 2 g/kg body weight every 2 months for 2 years
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transfer factor 1 i.u. (transfer factor group)
Number of subjects: 0
Study: 8215273

Group type: EXPERIMENTAL
Intervention: Cefprozil
Number of subjects: 323

Group type: COMPARATOR
Intervention: Penicillin V
Number of subjects: 323
Study: 2953771

Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal angioplasty
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Repeat coronary angioplasty
Number of subjects: 53
Study: 29523640

Group type: EXPERIMENTAL
Intervention: Baseline WMH volume
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: WMH progression
Number of subjects: 458

Group type: COMPARATOR
Intervention: Highest quartile of baseline WMH volume
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: Fast progression of WMH
Number of subjects: 458
Study: 24317461

Group type: EXPERIMENTAL
Intervention: 7-T FLAIR* MRI technique
Number of subjects: 32
Study: 22323352

Group type: EXPERIMENTAL
Intervention: Physical training 2 x 45 minutes per week for 3 months
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Individual nutritional advice and group sessions on nutrition for the elderly
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Combined nutritional and physical intervention
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 96
Study: 20630294

Group type: EXPERIMENTAL
Intervention: ProTaper system
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: EndoSequence system
Number of subjects: 22
Study: 18393054

Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone treatment
Number of subjects: 53
Study: 15533536

Group type: EXPERIMENTAL
Intervention: Brief advice plus more extended counseling during and after hospitalization (A + C)
Number of subjects: 2095

Group type: COMPARATOR
Intervention: Modified usual care (UC)
Number of subjects: 2095

Group type: COMPARATOR
Intervention: Brief advice (A)
Number of subjects: 2095
Study: 12429897

Group type: EXPERIMENTAL
Intervention: Eccentric muscle contractions (240 repetitions, 30 degrees/s)
Number of subjects: 5
Study: 10471565

Group type: EXPERIMENTAL
Intervention: Sulfadoxine (Sdx) and pyrimethamine (Pyr) combinations
Number of subjects: 252
Study: 8853530

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HDC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HDC) as consolidation therapy
Number of subjects: 0
Study: 2186651

Group type: EXPERIMENTAL
Intervention: diclofenac 75 mg intramuscularly
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: nefopam 20 mg intramuscularly
Number of subjects: 82

Group type: COMPARATOR
Intervention: oral paracetamol as required
Number of subjects: 82
Study: 252699

Group type: EXPERIMENTAL
Intervention: Topical application of ten units of regular insulin (U.S.P.) twice daily
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 29
Study: 31877117

Group type: EXPERIMENTAL
Intervention: Exenatide (GLP-1 analog)
Number of subjects: 0
Study: 31764368

Group type: EXPERIMENTAL
Intervention: Trained group (completed 9 simulator-based training modules)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Untrained group (no training modules)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Trained group
Number of subjects: 24
Study: 27734550

Group type: EXPERIMENTAL
Intervention: Percutaneous radiofrequency treatment applied to the ramus communicans
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham procedure (same procedure except radiofrequency treatment)
Number of subjects: 60
Study: 26543357

Group type: EXPERIMENTAL
Intervention: Linseed oil supplementation (3 g/day)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 23601899

Group type: EXPERIMENTAL
Intervention: Roux-en-Y reconstruction (RYR)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Conventional loop reconstruction (CLR)
Number of subjects: 216
Study: 21824948

Group type: EXPERIMENTAL
Intervention: Frequent intervention group (n = 311)
Number of subjects: 641

Group type: COMPARATOR
Intervention: Control group (n = 330)
Number of subjects: 641

Group type: EXPERIMENTAL
Intervention: Frequent intervention group (n = 311) with impaired glucose tolerance at baseline
Number of subjects: 641

Group type: EXPERIMENTAL
Intervention: Frequent intervention group (n = 311) with baseline hemoglobin A(1c) levels of 5.6% or more
Number of subjects: 641
Study: 19853772

Group type: EXPERIMENTAL
Intervention: Bipolar scissors circumcision
Number of subjects: 230

Group type: COMPARATOR
Intervention: Standard scalpel technique
Number of subjects: 230
Study: 16990660

Group type: EXPERIMENTAL
Intervention: Lowest birth weight (<2500 g)
Number of subjects: 973

Group type: COMPARATOR
Intervention: Highest birth weight (≥3500 g)
Number of subjects: 973

Group type: EXPERIMENTAL
Intervention: Abdominal obesity
Number of subjects: 973

Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 973
Study: 15589067

Group type: EXPERIMENTAL
Intervention: Sibutramine (10 mg/d, n = 22)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Orlistat (3 x 120 mg/d, n = 25)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Combination therapy (10 mg sibutramine/d + 3 x 120 mg orlistat/d, n = 20)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Diet alone (n = 19)
Number of subjects: 86
Study: 11394194

Group type: EXPERIMENTAL
Intervention: Pretreatment with a balanced amino acid mixture followed by pentagastrin (0.6 microgram/kg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Pretreatment with a balanced amino acid mixture followed by normal saline placebo
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Pretreatment with an amino acid mixture without phenylalanine or tyrosine followed by pentagastrin (0.6 microgram/kg)
Number of subjects: 6
Study: 9351695

Group type: EXPERIMENTAL
Intervention: Resistance exercise for 50 min at 70% of maximum (N=15)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cycling for 50 min at 70% of maximum (N=15)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Autogenic relaxation for 50 min (N=15)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Quiet rest for 50 min (N=15)
Number of subjects: 30
Study: 7899678

Group type: EXPERIMENTAL
Intervention: Rehabilitation training for four months (group 1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Usual activity (control group, group 2)
Number of subjects: 20
Study: 3236760

Group type: EXPERIMENTAL
Intervention: Combined exercise and low-fat dietary regimen
Number of subjects: 11

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 11
Study: 29084091

Group type: EXPERIMENTAL
Intervention: 3-second isometric exercise protocol (P3)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 6-second isometric exercise protocol (P6)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Comparison of P3 and P6
Number of subjects: 14
Study: 27207349

Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (5-FU)
Number of subjects: 0
Study: 25909406

Group type: EXPERIMENTAL
Intervention: Ketamine/propofol admixture (ketofol)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Etomidate
Number of subjects: 160
Study: 23885610

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with rehabilitation therapy (group A)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Rehabilitation therapy alone (group B)
Number of subjects: 86
Study: 19806358

Group type: EXPERIMENTAL
Intervention: Behavioral intervention for weight loss (12 months)
Number of subjects: 127
Study: 18926581

Group type: EXPERIMENTAL
Intervention: Capsular distension and rehabilitation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Rehabilitation only
Number of subjects: 60
Study: 16740370

Group type: EXPERIMENTAL
Intervention: Baclofen (20 mg tid)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Gabapentin (800 mg tid)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 14658397

Group type: EXPERIMENTAL
Intervention: 123I‐MIBG scintigraphy
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: QTc interval measurement
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Valsalva maneuver
Number of subjects: 62
Study: 11011328

Group type: EXPERIMENTAL
Intervention: Provisional stenting
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Primary stenting
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional PTCA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Contemporary CABG
Number of subjects: 0
Study: 8783056

Group type: EXPERIMENTAL
Intervention: ePTFE+DFDBA (experimental)
Number of subjects: 25

Group type: COMPARATOR
Intervention: ePTFE alone (control)
Number of subjects: 25
Study: 1293261

Group type: EXPERIMENTAL
Intervention: 3 mg preservative-free morphine
Number of subjects: 42

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 42
Study: 6315442

Group type: EXPERIMENTAL
Intervention: ER+ tumours
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: ER+PgR+ tumours
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Grade 1 or 2 tumours (in ER+ patients)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Grade 1 or 2 tumours (in patients with nodal involvement)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Better-differentiated (grade 1 and 2) tumours
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: ER+ tumours (in patients with no evidence of axillary nodal involvement)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Histological grade
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: ER content
Number of subjects: 400
Study: 30558805

Group type: EXPERIMENTAL
Intervention: Short forearm splint for two weeks postoperatively
Number of subjects: 39

Group type: COMPARATOR
Intervention: Conventional bandage with early wrist mobilization
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: No splint group
Number of subjects: 39

Group type: COMPARATOR
Intervention: Splint group
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 39
Study: 29020373

Group type: EXPERIMENTAL
Intervention: Artemether-Lumefantrine (AL) - total target dose: 12 mg/kg for artemether and 60 mg/kg for lumefantrine
Number of subjects: 123

Group type: COMPARATOR
Intervention: Chloroquine (CQ) - dosage: 25 mg/kg
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Artemether-Lumefantrine (AL)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Chloroquine (CQ)
Number of subjects: 123
Study: 27159308

Group type: EXPERIMENTAL
Intervention: High-tension group (overconstrain AP laxity by 2 mm)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Low-tension group (restore normal AP laxity)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: High-tension group
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Low-tension group
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (matched uninjured participants)
Number of subjects: 84
Study: 25280578

Group type: EXPERIMENTAL
Intervention: Discussion arm (discussion about the meaning and implication of test results, delivered by a nurse before tests in clinic, plus a pre-test pamphlet)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Pamphlet arm (pre-test pamphlet alone)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Discussion arm
Number of subjects: 120

Group type: COMPARATOR
Intervention: Pamphlet arm
Number of subjects: 120
Study: 22283238

Group type: EXPERIMENTAL
Intervention: Timolol XE
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Brinzolamide
Number of subjects: 60
Study: 21067078

Group type: EXPERIMENTAL
Intervention: Vein-viewing device
Number of subjects: 91

Group type: COMPARATOR
Intervention: Baseline data (control group)
Number of subjects: 91
Study: 17884787

Group type: EXPERIMENTAL
Intervention: CMF regimen
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: CEF regimen
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: NEF regimen
Number of subjects: 132
Study: 15172468

Group type: EXPERIMENTAL
Intervention: externally‐irrigated catheter
Number of subjects: 80

Group type: COMPARATOR
Intervention: internally‐cooled catheter
Number of subjects: 80

Group type: COMPARATOR
Intervention: single sensor, 8‐mm tip catheter
Number of subjects: 80

Group type: COMPARATOR
Intervention: double sensor, 8‐mm tip catheter
Number of subjects: 80
Study: 11748437

Group type: EXPERIMENTAL
Intervention: Skeletonized IMA (Group I)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Pedicled IMA (Group II)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Semiskeletonized IMA (Group III)
Number of subjects: 33
Study: 9853926

Group type: EXPERIMENTAL
Intervention: High phenylalanine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Moderate phenylalanine
Number of subjects: 16
Study: 7863813

Group type: EXPERIMENTAL
Intervention: Low-dose IL-2 (3 million IU/day for 6 days/week)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Epirubicin (25 mg/m2 i.v. weekly)
Number of subjects: 7
Study: 2488472

Group type: EXPERIMENTAL
Intervention: Glucagon (0.5 mg i.v. bolus followed by 1.5 mg infused over 90 minutes)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Glucagon
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 30334954

Group type: EXPERIMENTAL
Intervention: TaperGuard endotracheal tube secured on the same side as head rotation (Group S, n = 29)
Number of subjects: 58

Group type: COMPARATOR
Intervention: TaperGuard endotracheal tube secured on the opposite side of head rotation (Group O, n = 29)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: TaperGuard endotracheal tube secured on the same side as head rotation (Group S)
Number of subjects: 58

Group type: COMPARATOR
Intervention: TaperGuard endotracheal tube secured on the opposite side of head rotation (Group O)
Number of subjects: 58
Study: 28797307

Group type: EXPERIMENTAL
Intervention: Ecological Momentary Assessments (EMAs) only
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Ecological Momentary Interventions (EMIs) only
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Combined EMAs + EMIs
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control condition without EMA or EMI
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: All groups (including control)
Number of subjects: 400
Study: 26641099

Group type: EXPERIMENTAL
Intervention: 12-week online mindfulness training in addition to usual care (UC)
Number of subjects: 324

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 324
Study: 23595161

Group type: EXPERIMENTAL
Intervention: CALM-BP treatment (rice diet, walks, yoga, relaxation and stress management)
Number of subjects: 113

Group type: COMPARATOR
Intervention: DASH+exercise control group (DASH and walks)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: CALM-BP treatment
Number of subjects: 113

Group type: COMPARATOR
Intervention: DASH+exercise control group
Number of subjects: 113
Study: 21131550

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Propofol and Remifentanil
Number of subjects: 120
Study: 18652319

Group type: EXPERIMENTAL
Intervention: Routine comprehensive therapy and moxibustion at Zusanli (ST 36), Guanyuan (CV 4), Sanyinjiao (SP 6)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Routine comprehensive therapy (including hemodialysis and medication)
Number of subjects: 71
Study: 16950175

Group type: EXPERIMENTAL
Intervention: Niacin treatment for 3 months
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 14505772

Group type: EXPERIMENTAL
Intervention: Mailed thank-you card, patient newsletters, and reminder (maximum group)
Number of subjects: 1558

Group type: COMPARATOR
Intervention: No mailings (control group)
Number of subjects: 1558

Group type: EXPERIMENTAL
Intervention: Survey estimates (response rate 80%)
Number of subjects: 1558
Study: 10766318

Group type: EXPERIMENTAL
Intervention: Triple therapy with amoxicillin, clarithromycin, pantoprazole
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Triple therapy with tinidazole, clarithromycin, ranitidine bismuth citrate
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Triple therapy with tinidazole, clarithromycin, pantoprazole
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Quadruple therapy with tinidazole, tetracycline, bismuth, and pantoprazole
Number of subjects: 172

Group type: COMPARATOR
Intervention: Triple therapies (all regimens)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Quadruple therapy
Number of subjects: 172
Study: 8823232

Group type: EXPERIMENTAL
Intervention: Lamotrigine (50 mg/day)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Lamotrigine (100 mg/day)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Lamotrigine (150 mg/day)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Valproate (500 mg Depakote twice a day)
Number of subjects: 18